NasdaqCM - Nasdaq Real Time Price USD

Fennec Pharmaceuticals Inc. (FENC)

9.24 +0.08 (+0.87%)
As of 2:31 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Rostislav Raykov CEO & Director 885.07k -- 1976
Mr. Robert C. Andrade Chief Financial Officer 600.88k -- 1975
Mr. Adrian J. Haigh Chief Operating Officer 394.19k -- 1959
Mr. Mark Gowland Controller -- -- --
Mr. Lei Fang President of Pharstat Inc -- -- --

Fennec Pharmaceuticals Inc.

68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
United States
919 636 4530 https://www.fennecpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
29

Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Corporate Governance

Fennec Pharmaceuticals Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 5; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Fennec Pharmaceuticals Inc. Earnings Call

Related Tickers

NGEN.V NervGen Pharma Corp.
2.1600
+6.93%
 
NGENF NervGen Pharma Corp.
1.5300
+2.00%
 
TARA Protara Therapeutics, Inc.
2.9300
-3.93%
 
EPRX.TO Eupraxia Pharmaceuticals Inc.
3.7700
-3.33%
 
VSC.F 4SC AG
8.86
-0.23%
 
DSGN Design Therapeutics, Inc.
3.7650
+0.13%
 
IMMU.ST Mendus AB (publ)
0.4745
+0.96%
 
ANEB Anebulo Pharmaceuticals, Inc.
2.7036
+1.26%
 
SLNCF Silence Therapeutics plc
8.00
0.00%
 
CSBR Champions Oncology, Inc.
5.06
0.00%